 |
|
|
| |
Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis
|
| |
| |
Reported by Jules Levin
EASL 2014 April 10-13 London, UK
Mark S Sulkowski,1 Ira M Jacobson,2 Reem Ghalib,3 Maribel Rodriguez-Torres,4 Zobair Younossi,5 Ana Corregidor,6 Bart Fevery,7 Katleen Callewaert,8 William Symonds,9 Guy De La Rosa,10 Gaston Picchio,11 Sivi Ouwerkerk-Mahadevan,7 Tom Lambrecht,12 Eric Lawitz13
1Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Weill Cornell Medical College, New York, NY, USA; 3Texas Clinical Research Institute, Arlington, Texas, USA; 4Fundación de Investigación, San Juan, Puerto Rico, USA; 5Department of Internal Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 6Borland-Groover Clinic, Jacksonville, FL, USA; 7Janssen Research & Development, Janssen Infectious Diseases BVBA, Beerse, Belgium; 8Janssen Research & Development, Beerse, Belgium; 9Gilead Sciences, Inc. Foster City, CA, USA; 10Janssen Global Services, Titusville, NJ, USA; 11Janssen Research & Development LLC, Titusville, NJ, USA; 12Novellas Healthcare, Zellik, Belgium; 13The Texas Liver Institute, University of Texas Health Science Center,
San Antonio, TX, USA
|
| |
|
|
|
|
|
